Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
Providence Gold Mines Inc. Receives Regulatory Approvals for Fundamental Transaction & The La Dama de Oro Gold Property NI 43-101 Report
